

# OIE Reference Laboratory Reports Activities

## *Activities in 2021*

**This report has been submitted : 2022-01-13 20:57:35**

<b>Name of disease (or topic) for which you are a designated OIE Reference Laboratory:</b>	Infection with infectious salmon anaemia virus
<b>Address of laboratory:</b>	Aquaculture Pathology Laboratory, Genetic and Molecular Immunology Laboratory of the Pontifical Catholic University of Valparaíso, Avenida Universidad, 330 Valparaíso, CHILE
<b>Tel.:</b>	+56-32 227.48.28
<b>Fax:</b>	
<b>E-mail address:</b>	sergio.marshall@pucv.cl
<b>Website:</b>	
<b>Name (including Title) of Head of Laboratory (Responsible Official):</b>	Sergio Hernán Marshall González Ph.D. Harvard University - USA. Microbiology and Molecular Genetics. MSc. Biology. Brandeis University - USA. BA. Biology - Brandeis University - USA. Licenciatura en Biología. PUCV - Chile.
<b>Name (including Title and Position) of OIE Reference Expert:</b>	Sergio Hernán Marshall González Ph.D. Harvard University - USA. Microbiology and Molecular Genetics. MSc. Biology. Brandeis University - USA. BA. Biology - Brandeis University - USA. Licenciatura en Biología. PUCV - Chile.
<b>Which of the following defines your laboratory? Check all that apply:</b>	Governmental Academic

***ToR 1: To use, promote and disseminate diagnostic methods validated according to OIE Standards***

1. Did your laboratory perform diagnostic tests for the specified disease/topic for purposes such as disease diagnosis, screening of animals for export, surveillance, etc.? (Not for quality control, proficiency testing or staff training)

No

***ToR 2: To develop reference material in accordance with OIE requirements, and implement and promote the application of OIE Standards. To store and distribute to national laboratories biological reference products and any other reagents used in the diagnosis and control of the designated pathogens or disease.***

2. Did your laboratory produce or supply imported standard reference reagents officially recognised by the OIE?

No

3. Did your laboratory supply standard reference reagents (non OIE-approved) and/or other diagnostic reagents to OIE Member Countries?

Yes

Type of reagent available	Related diagnostic test	Produced/ provide	Amount supplied nationally (ml, mg)	Amount supplied internationally (ml, mg)	No. of recipient OIE Member Countries	Region of recipients
Primers y Sondas	RT-qPCR AISA	Primers y sondas S6 y S5	100 uL por cada tripleta	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Aislados ISAV HPR3a	RT-qPCR AISA	RNA	50 uL	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Aislados ISAV HPR 8a	RT-qPCR	RNA	50 uL	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Aislados ISAV HPR 0a	RT-qPCR	RNA	50 uL	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East
Aislados ISAV HPR 14a	RT-qPCR	RNA	50 uL	0	1	<input type="checkbox"/> Africa <input checked="" type="checkbox"/> Americas <input type="checkbox"/> Asia and Pacific <input type="checkbox"/> Europe <input type="checkbox"/> Middle East

4. Did your laboratory produce vaccines?

No

5. Did your laboratory supply vaccines to OIE Member Countries?

No

**ToR 3: To develop, standardise and validate, according to OIE Standards, new procedures for diagnosis and control of the designated pathogens or diseases**

6. Did your laboratory develop new diagnostic methods validated according to OIE Standards for the designated pathogen or disease?

No

7. Did your laboratory develop new vaccines according to OIE Standards for the designated pathogen or disease?

No

**ToR 4: To provide diagnostic testing facilities, and, where appropriate, scientific and technical advice on disease control measures to OIE Member Countries**

8. Did your laboratory carry out diagnostic testing for other OIE Member Countries?

No

9. Did your laboratory provide expert advice in technical consultancies on the request of an OIE Member Country?

Yes

Name of the OIE Member Country receiving a technical consultancy	Purpose	How the advice was provided
CHILE	Validación de ensayo RT-qPCR AISA	Servicio de Validación técnica
CHILE	Asesoría técnica a Sernapesca en la propuesta de actualización del capítulo de ISAV del Manual de Animales Acuáticos OIE	Reuniones virtuales y revisión de bibliografía científica y antecedentes epidemiológicos

**ToR 5: To carry out and/or coordinate scientific and technical studies in collaboration with other laboratories, centres or organisations**

10. Did your laboratory participate in international scientific studies in collaboration with OIE Member Countries other than the own?

No

**ToR 6: To collect, process, analyse, publish and disseminate epizootiological data relevant to the designated pathogens or diseases**

11. Did your Laboratory collect epizootiological data relevant to international disease control?

No

If the answer is no, please provide a brief explanation of the situation:

La situación sanitaria que se vive a nivel mundial por la pandemia de SARS CoV-2 obligó a las autoridades de nuestro país a ajustar presupuestos y destinar recursos a la ayuda social de la población que sufrió el azote de la pandemia y debió cerrar sus negocios. A causa de lo anterior el presupuesto con el que anualmente cuenta Sernapesca para realizar análisis de verificación se vio mermado y la vigilancia quedo reducida a lo estrictamente necesario, lo que es mandado por el Programa sanitario específico de vigilancia y control de ISAV (PSEVC-ISA). Es por ello que nuestro laboratorio no produjo datos epidemiológicos durante este año.

12. Did your laboratory disseminate epizootiological data that had been processed and analysed?

No

If the answer is no, please provide a brief explanation of the situation:

La situación sanitaria que se vive a nivel mundial por la pandemia de SARS CoV-2 obligó a mantener nuestro laboratorio semi-cerrado gran parte del año, lo que no nos permitió el acceso acceso a muestras que pudiesemos analizar para producir datos epidemiológicos.

**13. What method of dissemination of information is most often used by your laboratory? (Indicate in the appropriate box the number by category)**

a) Articles published in peer-reviewed journals: 0

b) International conferences: 0

c) National conferences: 0

d) Other:  
(Provide website address or link to appropriate information) 0

**ToR 7: To provide scientific and technical training for personnel from OIE Member Countries  
To recommend the prescribed and alternative tests or vaccines as OIE Standards**

14. Did your laboratory provide scientific and technical training to laboratory personnel from other OIE Member Countries?

No

**ToR 8: To maintain a system of quality assurance, biosafety and biosecurity relevant for the pathogen and the disease concerned**

15. Does your laboratory have a Quality Management System?

No

Explain Quality Management System in adoption process or currently in place
Nuestro laboratorio trabaja bajo los estándares de la NCh-ISO/IEC 17025:2017 y acreditado por el Instituto Nacional de Acreditación (INN). Esta acreditación venció en mayo del año 2020 y en estos momentos estamos en proceso de renovación.

16. Is your quality management system accredited?

No

17. Does your laboratory maintain a “biorisk management system” for the pathogen and the disease concerned?

No

*(See Manual of Diagnostic Tests and Vaccines for Terrestrial Animals, Chapter 1.1.4)*

**ToR 9: To organise and participate in scientific meetings on behalf of the OIE**

18. Did your laboratory organise scientific meetings on behalf of the OIE?

No

19. Did your laboratory participate in scientific meetings on behalf of the OIE?

No

**ToR 10: To establish and maintain a network with other OIE Reference Laboratories designated for the same pathogen or disease and organise regular inter-laboratory proficiency testing to ensure comparability of results**

20. Did your laboratory exchange information with other OIE Reference Laboratories designated for the same pathogen or disease?

No

21. Was your laboratory involved in maintaining a network with OIE Reference Laboratories designated for the same pathogen or disease by organising or participating in proficiency tests?

No

22. Did your laboratory collaborate with other OIE Reference Laboratories for the same disease on scientific research projects for the diagnosis or control of the pathogen of interest?

No

**ToR 11: To organise inter-laboratory proficiency testing with laboratories other than OIE Reference Laboratories for the same pathogens and diseases to ensure equivalence of results**

23. Did your laboratory organise or participate in inter-laboratory proficiency tests with laboratories other than OIE Reference Laboratories for the same disease?

No

Note: See Interlaboratory test comparisons in: Laboratory Proficiency Testing at: <http://www.oie.int/en/our-scientific-expertise/reference-laboratories/proficiency-testing> see point 1.3

**ToR 12: To place expert consultants at the disposal of the OIE**

24. Did your laboratory place expert consultants at the disposal of the OIE?

Yes

Kind of consultancy	Location	Subject (facultative)
Revisión y aportes en el Capítulo de ISAV del Manual de Pruebas de Diagnóstico para los Animales Acuáticos	Chile	Actualización capítulo de ISAV del Manual de Pruebas de Diagnóstico para los Animales Acuáticos

25. Additional comments regarding your report:

La situación sanitaria que se vive a nivel mundial por la pandemia de SARS CoV-2 nos obligó a suspender o disminuir en gran medida nuestras actividades en el ámbito del diagnóstico e investigación acuícola

Sin perjuicio de lo anterior, la situación de ISAV en nuestro país ha estado relativamente tranquila con detección de casos aislados durante el año y sin mayores repercusiones.

Respecto a la situación de ISAV HPR0 se mantiene con un nivel de detección relativamente bajo y sin relación con mortalidad de peces ni enfermedad clínica.